

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

INSIDE INFORMATION UPDATE ON LITIGATION

This announcement is made by Sanai Health Industry Group Company Limited (the “**Company**“, together with its subsidiaries, collectively the “**Group**“) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**“) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the paragraph headed “Litigation” of the Directors’ Report in the annual report of the Company for the year ended 31 December 2024, and the announcements of the Company dated 18 January 2021, 4 February 2021, 1 June 2023, 19 December 2023 and 12 May 2025 respectively (collectively the “**Announcements**“) in relation to the Litigation and the Appeal. Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcements.

The Board wishes to announce that the Company has lodged an appeal (the “**Second Appeal**“) against the Second Civil Judgement to 北京市高級人民法院 (the High People’s Court of Beijing*) on 23 May 2025.

Pursuant to the Second Appeal, the Company has pleaded to 北京市高級人民法院 (the High People’s Court of Beijing*) to rule that the Finance Lease Agreement and the Guarantee were invalid, and to reject all of the Plaintiff’s claims.

The Company will publish further announcement(s) in respect of any significant development of the Litigation, including the Second Appeal, in compliance with the Listing Rules as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sanai Health Industry Group Company Limited
She Hao
Executive Director

Hong Kong, 23 May 2025

As at the date of this notice, the Board comprises five executive directors, namely, Mr. Chen Chengqing, Mr. Yuan Chaoyang, Professor Zhang Rongqing, Mr. She Hao and Mr. Xie Haijing, and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Ms. Tsui Yuen Tan.